Who is Thomas Strüngmann?
Thomas Strüngmann is the co-founder of Hexal, which he sold to Novartis. He was born on February 16, 1950. He is married to Connie Strungmann. They have 4 children: Fiona Strüngmann, Felix Strüngmann, Fabian Strüngmann, and Agustina Strüngmann.
Thomas co-founded Hexal in 1986. The company launched the very successful cholesterol-lowering drug simvastatin, a replacement for Merck’s drug called Zocor.
In 2005, Thomas Strüngmann and his twin brother Andreas sold Hexal to Novartis for around $7 billion.
The brothers invest in biotech, pharmaceutical, life science, and health companies through their Zug-based investment company Santo Holding. Their portfolio includes the German Biontech and the Uruguayan Mega Pharma, originally a joint venture with the Argentine billionaire Alberto Roemmers. In April 2020, Biontech received approval to test four vaccines against Covid-19.
The development costs are largely borne by the US pharmaceutical company Pfizer and the Chinese company Fosun Pharma.
In 2008, the Strüngmann brothers also founded a neuroscientific research center in Frankfurt, which was named after their father Ernst Strüngmann.
Thomas Strungman Net Worth
His net worth is $3.5 billion.
Message to Other Media
Please mention SuperYachtFan when using this information.